An ultra-sensitive, ultra-fast whole blood monocyte CD169 assay for COVID-19 screening
Abstract CoVID-19 is an unprecedented epidemic, globally challenging health systems, societies, and economy. Its diagnosis relies on molecular methods, with drawbacks revealed by current use as mass screening. Monocyte CD169 upregulation has been reported as a marker of viral infections, we evaluated a flow cytometry three-color rapid assay of whole blood monocyte CD169 for CoVID-19 screening.Outpatients (n=177) with confirmed CoVID-19 infection, comprising 80 early-stage (≤14 days after symptom onset), 71 late-stage (≥15 days), and 26 asymptomatic patients received whole blood CD169 testing in parallel with SARS-CoV-2 RT-PCR. Upregulation of monocyte CD169 without polymorphonuclear neutrophil CD64 changes was the primary endpoint. Sensitivity was 98% and 100% in early-stage and asymptomatic patients respectively, specificity was 50% and 84%. Rapid whole blood monocyte CD169 evaluation was highly sensitive when compared with RT-PCR, especially in early-stage, asymptomatic patients whose RT-PCR tests were not yet positive.Diagnostic accuracy, easy finger prick sampling and minimal time-to-result (15-30 minutes) rank whole blood monocyte CD169 upregulation as a potential screening and diagnostic support for CoVID-19. Secondary endpoints were neutrophil CD64 upregulation as a marker of bacterial infections and monocyte HLA-DR downregulation as a surrogate of immune fitness, both assisting with adequate and rapid management of non-CoVID cases..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 30. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michel, Moïse [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.10.22.20215749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019215207 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019215207 | ||
| 003 | DE-627 | ||
| 005 | 20240502091718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201028s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.10.22.20215749 |2 doi | |
| 035 | |a (DE-627)XBI019215207 | ||
| 035 | |a (biorXiv)10.1101/2020.10.22.20215749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michel, Moïse |e verfasserin |0 (orcid)0000-0002-0460-9898 |4 aut | |
| 245 | 1 | 0 | |a An ultra-sensitive, ultra-fast whole blood monocyte CD169 assay for COVID-19 screening |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract CoVID-19 is an unprecedented epidemic, globally challenging health systems, societies, and economy. Its diagnosis relies on molecular methods, with drawbacks revealed by current use as mass screening. Monocyte CD169 upregulation has been reported as a marker of viral infections, we evaluated a flow cytometry three-color rapid assay of whole blood monocyte CD169 for CoVID-19 screening.Outpatients (n=177) with confirmed CoVID-19 infection, comprising 80 early-stage (≤14 days after symptom onset), 71 late-stage (≥15 days), and 26 asymptomatic patients received whole blood CD169 testing in parallel with SARS-CoV-2 RT-PCR. Upregulation of monocyte CD169 without polymorphonuclear neutrophil CD64 changes was the primary endpoint. Sensitivity was 98% and 100% in early-stage and asymptomatic patients respectively, specificity was 50% and 84%. Rapid whole blood monocyte CD169 evaluation was highly sensitive when compared with RT-PCR, especially in early-stage, asymptomatic patients whose RT-PCR tests were not yet positive.Diagnostic accuracy, easy finger prick sampling and minimal time-to-result (15-30 minutes) rank whole blood monocyte CD169 upregulation as a potential screening and diagnostic support for CoVID-19. Secondary endpoints were neutrophil CD64 upregulation as a marker of bacterial infections and monocyte HLA-DR downregulation as a surrogate of immune fitness, both assisting with adequate and rapid management of non-CoVID cases. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Malergue, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Belkacem, Inès Ait |e verfasserin |4 aut | |
| 700 | 1 | |a Bourgoin, Pénélope |e verfasserin |4 aut | |
| 700 | 1 | |a Morange, Pierre-Emmanuel |e verfasserin |0 (orcid)0000-0002-9065-722X |4 aut | |
| 700 | 1 | |a Arnoux, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Miloud, Tewfik |e verfasserin |4 aut | |
| 700 | 1 | |a Million, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Tissot-Dupont, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Mege, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Busnel, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Vitte, Joana |e verfasserin |0 (orcid)0000-0002-3344-9408 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 30. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:30 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1177/20503121221115483 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.10.22.20215749 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 30 |c 04 | ||